Chapter 11. Human Immunodeficiency Virus

  1. Mark Loeb BSc, MD, MSc, FRCPC Professor3,4,
  2. Fiona Smaill MB, ChB, FRCPC Department Chair Professor of Pathology3 and
  3. Marek Smieja MD, DIP, MSc, PhD, FRCPC Associate Professor3,5
  1. Ravindra K. Gupta MD1 and
  2. Brian J. Angus BSC, MD Reader2

Published Online: 17 DEC 2009

DOI: 10.1002/9781444301601.ch11

Evidence-Based Infectious Diseases, Second Edition

Evidence-Based Infectious Diseases, Second Edition

How to Cite

Gupta, R. K. and Angus, B. J. (2009) Human Immunodeficiency Virus, in Evidence-Based Infectious Diseases, Second Edition (eds M. Loeb, F. Smaill and M. Smieja), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444301601.ch11

Editor Information

  1. 3

    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada

  2. 4

    Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada

  3. 5

    Department of Medicine, McMaster University, Hamilton, Ontario, Canada

Author Information

  1. 1

    Centre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, UK

  2. 2

    University of Oxford, Nuffield Department of Medicine, John Radcliffe Hospital, Oxford, UK

Publication History

  1. Published Online: 17 DEC 2009
  2. Published Print: 28 AUG 2009

ISBN Information

Print ISBN: 9781405170260

Online ISBN: 9781444301601

SEARCH

Keywords:

  • human immunodeficiency virus;
  • primary HIV infection (PHI);
  • asymptomatic HIV infection;
  • epidemiology of drug resistance, baseline genotyping, and response to HAART;
  • European study, CATCH - assessing resistance in newly infected people;
  • transmitted drug resistant virus (TDR) - in cohorts of seroconverters;
  • antituberculosis prophylaxis;
  • side effects and drug–drug interactions associated with HAART;
  • prophylaxis for PCP;
  • therapeutic drug monitoring - pharmacologic substudy of VIRADAPT

Summary

This chapter contains sections titled:

  • Primary HIV infection Tuberculosis

  • pneumonia

  • Antiretroviral regimen selection and adherence

  • Opportunistic infection prophylaxis

  • Viral phenotyping

  • Genotypic resistance testing

  • Therapeutic drug monitoring

  • Management of multiple resistance

  • Treatment and prophylaxis of opportunistic infections (continued)

  • Other AIDS-related illness

  • References